" class="no-js "lang="en-US"> YDS Pharmatech Appoints New Head of Medicinal Chemistry
Saturday, April 20, 2024

YDS Pharmatech Appoints Dr. Robert Sullivan as Head of Medicinal Chemistry

YDS Pharmatech, a computational drug discovery company specializing in induced proximity, today announced the appointment of Robert Sullivan as Head of Medicinal Chemistry. With over 20 years of experience in the field, Dr. Sullivan possesses expertise in small molecules, PROTACs, peptides, and oligonucleotides.

Dr. Sullivan previously served as Head of Preclinical Development at BioTheryX, where he played a pivotal role in creating the Cereblon binding library and directed research that led to more than 20 issued patents. These patents encompass a broad range of small molecules (molecular glues) and PROTACs. Before BioTheryX, Dr. Sullivan held the position of Executive Director of Drug Development at NovoMedix, where he contributed to the drug discovery efforts for antifibrotic and breast cancer development candidates entering IND-enabling studies.

Over the course of his distinguished career, Dr. Sullivan has held leadership positions at PYC Therapeutics, Protagonist, Amylin Pharmaceuticals, Kemia, Neurocrine, and Signal Pharmaceuticals. As one of the pioneering scientists in high throughput parallel synthesis technologies and combinatorial chemistry, he has co-authored over 20 peer-reviewed publications. Dr. Sullivan earned his B.S. in Chemistry from the University of California, Santa Barbara, and a Ph.D. in Chemistry from the University of California, Irvine.

“We are thrilled to welcome Dr. Robert Sullivan to the YDS Pharmatech team,” said Dr. Xing Che, CEO of YDS Pharmatech. “His extensive experience in targeted protein degrader discovery is invaluable to us. Dr. Sullivan’s expertise will enhance YDS’s ability to bridge the gap between computational scientists, biologists, and chemists, fostering more efficient integrated research. As a result, our computational platform for rationalizing drug discovery of protein degraders will see accelerated development.

“I am truly excited to join such a dynamic organization like YDS Pharmatech. YDS’s unique platform of combining AI and biophysics simulations to help drive drug discovery and development are second to none,” said Robert Sullivan, Head of Medicinal Chemistry at YDS Pharmatech. “I look forward to working with the YDS team and it’s partners to create drugs that address unmet medical needs.”

Dr. Sullivan’s appointment as Head of Medicinal Chemistry bolsters YDS Pharmatech’s dedication to remaining at the cutting edge of combining AI and biophysics simulations for induced proximity drug discovery. This state-of-the-art approach ensures that YDS Pharmatech stays at the forefront of innovation, while providing valuable support to partner companies collaborating with YDS to create groundbreaking medicines that address unmet medical needs.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more